1887

Abstract

It has been proposed that patients who develop -associated disease (CDAD) do so because they are unable to mount an adequate immune response. Serum was collected from three groups of elderly in-patients: (i) cases (=21) of CDAD, being toxin A/B-positive; (ii) carriers (=21) asymptomatic for CDAD (no diarrhoea) but at least toxin or culture positive; and (iii) controls (=26) asymptomatic for CDAD and negative for both toxin and culture. The age and gender of each group were compared, and the colonizing strains were ribotyped and toxinotyped. Serum antibodies (IgG and IgM) were measured by ELISA using different antigen preparations: EDTA extract (containing cell-surface proteins and carbohydrates), guanidine hydrochloride extract (surface-layer proteins), aqueous phenol-extracted lipocarbohydrate (LC); crude toxin (dialysis culture supernatant) and purified toxin A. LPS from was used as a control antigen. Antibodies were also tested for toxin neutralization on tissue monolayers and for binding to EDTA-extracted antigens by Western blotting. IgG antibody measurements to cytomegalovirus (CMV) were included as an indicator of potential immunosenescence. Results showed that the patient groups were well matched by age and gender, and the colonizing strains were similar in cases and carriers, being predominantly ribotype 001 and toxinotype 0. By ELISA, IgG levels to most of the antigens were highest in the cases and lowest in the controls, with the exception of antibodies to the LC, which were higher in the controls than the cases. Levels in the carriers tended to be of intermediate level or similar to the controls. For all antigens, the levels of IgM were not significantly different among cases, carriers and controls. Serum from all groups was able to neutralize the cytotoxic action of toxin on both Vero and Caco2 cells, and all to a similar extent. Western blots showed an overall higher level of IgG antibodies to the EDTA-extracted antigens in the cases. The results of the CMV ELISA showed that specific IgG was detected in more cases (78 %) than carriers and controls (both 65 %), but this difference in seropositivity was not significant. The conclusion is that, during symptomatic infection, patients respond to protein antigens of in a manner typical of a secondary antibody response, with no evidence that an inability to respond predisposes to the appearance of symptoms.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.47713-0
2008-06-01
2019-10-14
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/6/717.html?itemId=/content/journal/jmm/10.1099/jmm.0.47713-0&mimeType=html&fmt=ahah

References

  1. Bartlett, J. G. ( 2006; ). Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145, 758–764.[CrossRef]
    [Google Scholar]
  2. Bennett-Guerrero, E., Ayuso, L., Hamilton-Davies, C., White, W. D., Barclay, G. R., Smith, P. K., King, S. A., Muhlbaier, L. H., Newman, M. F. & Mythen, M. G. ( 1997; ). Relationship of preoperative anti-endotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 277, 646–650.[CrossRef]
    [Google Scholar]
  3. Cadena, J., Owens, A., Blankenship, J. & Chung, R. ( 2007; ). Cytomegalovirus pseudomembranous colitis in an immunocompetent patient: case report and review of the literature. Infect Dis Clin Pract 15, 213–216.[CrossRef]
    [Google Scholar]
  4. Deacon, A. G., Duerden, B. I. & Holbrook, W. P. ( 1978; ). Gas-liquid chromatographic analysis of metabolic products in the identification of Bacteroidaceae of clinical interest. J Med Microbiol 11, 81–99.[CrossRef]
    [Google Scholar]
  5. Drudy, D., Calabi, E., Kyne, L., Sougioultzis, S., Kelly, E., Fairweather, N. & Kelly, C. P. ( 2004; ). Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol Med Microbiol 41, 237–242.[CrossRef]
    [Google Scholar]
  6. Gibbs, R. J., Stewart, J. & Poxton, I. R. ( 2004; ). The distribution of, and antibody response to, the core lipopolysaccharide region of Escherichia coli isolated from the faeces of healthy humans and cattle. J Med Microbiol 53, 959–964.[CrossRef]
    [Google Scholar]
  7. Ives, D. V. & Smith, R. N. ( 1996; ). Case 17-1996. A 48-year-old man with the acquired immunodeficiency syndrome, abdominal pain, and bloody diarrhea. N Engl J Med 334, 1461–1468.[CrossRef]
    [Google Scholar]
  8. Johal, S. S., Lambert, C. P., Hammond, J., James, P. D., Borriello, S. P. & Mahida, Y. R. ( 2004; ). Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea. J Clin Pathol 57, 973–979.[CrossRef]
    [Google Scholar]
  9. Kamiya, S., Reed, P. J. & Borriello, S. P. ( 1989; ). Purification and characterisation of Clostridium difficile toxin A by bovine thyroglobulin affinity chromatography and dissociation in denaturing conditions with or without reduction. J Med Microbiol 30, 69–77.[CrossRef]
    [Google Scholar]
  10. Krivan, H. C. & Wilkins, T. D. ( 1987; ). Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun 55, 1873–1877.
    [Google Scholar]
  11. Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. ( 2000; ). Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342, 390–397.[CrossRef]
    [Google Scholar]
  12. Kyne, L., Warny, M., Qamar, A. & Kelly, C. P. ( 2001; ). Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189–193.[CrossRef]
    [Google Scholar]
  13. Looney, R. J., Falsey, A., Campbell, D., Torres, A., Kolassa, J., Brower, C., McCann, R., Menegus, M., McCormick, K. & other authors ( 1999; ). Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 90, 213–219.[CrossRef]
    [Google Scholar]
  14. McCoubrey, J. ( 2002; ). The epidemiology of Clostridium difficile in a geriatric unit. PhD thesis, University of Edinburgh, UK.
  15. Mulligan, M. E., Miller, S. D., McFarland, L. V., Fung, H. C. & Kwok, R. Y. ( 1993; ). Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 16 (Suppl. 4), S239–S244.[CrossRef]
    [Google Scholar]
  16. Mutlu, E., Wroe, A. J., Sánchez-Hurtado, K., Brazier, J. S. & Poxton, I. R. ( 2007; ). Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 56, 921–929.[CrossRef]
    [Google Scholar]
  17. O'Neill, G. L., Ogunsola, F. T., Brazier, J. S. & Duerden, B. I. ( 1996; ). Modification of a PCR ribotyping method for application as a routine typing scheme for Clostridium difficile. Anaerobe 2, 205–209.[CrossRef]
    [Google Scholar]
  18. Ogilvie, M. M. ( 2002; ). Herpes viruses. In Medical Microbiology. A Guide to Microbial Infections: Pathogenesis, Immunity, Laboratory Diagnosis and Control, 16th edn, pp. 399–420. Edited by D. Greenwood, R. C. B. Slack & J. F. Peutherer. Edinburgh: Churchill Livingstone.
  19. Olofinlade, O. & Chiang, C. ( 2001; ). Cytomegalovirus infection as a cause of pseudomembrane colitis: a report of four cases. J Clin Gastroenterol 32, 82–84.[CrossRef]
    [Google Scholar]
  20. Pawelec, G., Koch, S., Franceschi, C. & Wikby, A. ( 2006; ). Human immunosenescence: does it have an infectious component? Ann N Y Acad Sci 1067, 56–65.[CrossRef]
    [Google Scholar]
  21. Péchiné, S., Janoir, C. & Collignon, A. ( 2005; ). Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol 43, 5018–5025.[CrossRef]
    [Google Scholar]
  22. Péchiné, S., Janoir, C., Boureau, H., Gleizes, A., Tsapis, N., Hoys, S., Fattal, E. & Collignon, A. ( 2007; ). Diminished intestinal colonization by Clostridium difficile and immune response in mice after mucosal immunization with surface proteins of Clostridium difficile. Vaccine 25, 3946–3954.[CrossRef]
    [Google Scholar]
  23. Poxton, I. R. ( 1995; ). Antibodies to lipopolysaccharide. J Immunol Methods 186, 1–15.[CrossRef]
    [Google Scholar]
  24. Poxton, I. R. & Byrne, M. D. ( 1981; ). Immunological analysis of Clostridium difficile and related species. J Gen Microbiol 122, 41–46.
    [Google Scholar]
  25. Poxton, I. R. & Cartmill, T. D. I. ( 1982; ). Immunochemistry of the cell-surface carbohydrate antigens of Clostridium difficile. J Gen Microbiol 128, 1365–1370.
    [Google Scholar]
  26. Riva, G., Luppi, M., Potenzar, L., Morselli, M., Ferrari, A., Saviola, A., Volzone, F., Imovilli, A., Merighi, A. & other authors ( 2005; ). Cytomegalovirus and Clostridium difficile co-infection in severe ulcero-hemorrhagic colitis during induction chemotherapy for acute lymphoblastic leukemia. Haematologica 90, ECR01
    [Google Scholar]
  27. Rupnik, M., Braun, V., Soehn, F., Janc, M., Hofstetter, M., Laufenberg-Feldmann, R. & von Eichel-Streiber, C. ( 1997; ). Characterization of polymorphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiol Lett 148, 197–202.[CrossRef]
    [Google Scholar]
  28. Rupnik, M., Avesani, V., Janc, M., von Eichel-Streiber, C. & Delmée, M. ( 1998; ). A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36, 2240–2247.
    [Google Scholar]
  29. Sánchez-Hurtado, K. & Poxton, I. R. ( 2008; ). Enhancement of the cytotoxic activity of Clostridium difficile toxin A by surface-associated antigens. J Med Microbiol 57, 739–744.[CrossRef]
    [Google Scholar]
  30. Sharp, J. & Poxton, I. R. ( 1986; ). Analysis of the membrane lipocarbohydrate antigen of Clostridium difficile by polyacrylamide gel electrophoresis and immunoblotting. FEMS Microbiol Lett 34, 97–100.[CrossRef]
    [Google Scholar]
  31. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. & McDonald, L. C. ( 2005; ). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079–1084.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.47713-0
Loading
/content/journal/jmm/10.1099/jmm.0.47713-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error